Amid FTC crackdown, judge says Teva inhaler patents are 'improperly listed' in FDA Orange Book
Fierce Pharma
JUNE 12, 2024
A federal judge in New Jersey ruled that five of Teva’s patents on the metered dose inhaler for its asthma med ProAir HFA are “improperly listed” in the FDA’s Orange Book. The ruling came in Teva's case against Amneal Pharmaceuticals, which is seeking to launch a generic version of the drug.
Let's personalize your content